Cargando…

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma

Detalles Bibliográficos
Autores principales:	BEAUDOUX, Olivia, EHRET, Marine, CRIQUET, Emilie, FRANCESCHI, Joséphine, DURLACH, Anne, OUDART, Jean-Baptiste, VISSEAUX, Laetitia, GRANGE, Florent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society for Publication of Acta Dermato-Venereologica 2021
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364252/ https://www.ncbi.nlm.nih.gov/pubmed/33283249 http://dx.doi.org/10.2340/00015555-3715

Ejemplares similares

Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas
por: FRANCESCHI, Joséphine, et al.
Publicado: (2022)

Combination of pembrolizumab and imatinib in a patient with double KIT mutant melanoma: A case report
por: Abdou, Yara, et al.
Publicado: (2019)

The role of c-kit and imatinib mesylate in uveal melanoma
por: Pereira, Patricia Rusa, et al.
Publicado: (2005)

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT
por: Handolias, D, et al.
Publicado: (2010)

Lack of Response to Imatinib in Melanoma Carrying Rare KIT Mutation p.T632I
por: Orlova, Kristina V., et al.
Publicado: (2019)

LMTK3 is essential for oncogenic KIT expression in KIT-mutant GIST and melanoma
por: Klug, Lillian R., et al.
Publicado: (2018)

Imatinib mesylate in combination with pembrolizumab in patients with advanced KIT-mutant melanoma following progression on standard therapy: A phase I/II trial and study protocol
por: Hirai, Ikuko, et al.
Publicado: (2021)

Repurposing Ponatinib as a Potent Agent against KIT Mutant Melanomas
por: Han, Yong, et al.
Publicado: (2019)

Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma
por: Zukotynski, Katherine, et al.
Publicado: (2014)

Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo
por: Posch, Christian, et al.
Publicado: (2016)

Inhibition of c-Kit Is Not Required for Reversal of Hyperglycemia by Imatinib in NOD Mice
por: Lau, Janet, et al.
Publicado: (2014)

TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours
por: Saito, Yurina, et al.
Publicado: (2019)

Nuclear KIT induces a NFKBIB-RELA-KIT autoregulatory loop in imatinib-resistant gastrointestinal stromal tumors
por: Hsueh, Yuan-Shuo, et al.
Publicado: (2019)

Unusual penile localization of melanoma
por: Kaakoua, Mohamed, et al.
Publicado: (2022)

Sustained response to imatinib in patient with extraskeletal myxoid chondrosarcoma and novel KIT mutation
por: Jennings, Brooke, et al.
Publicado: (2021)

Lack of clinical efficacy of imatinib in metastatic melanoma
por: Ugurel, S, et al.
Publicado: (2005)

Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib
por: Zhu, Guangrong, et al.
Publicado: (2020)

KIT and PDGFRA Variants and the Survival of Patients with Gastrointestinal Stromal Tumor Treated with Adjuvant Imatinib
por: Joensuu, Heikki
Publicado: (2023)

Penile Exogenous Pigmentation Mimicking Melanoma
por: Vaccari, Sabina, et al.
Publicado: (2022)

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors
por: Liu, Xuechao, et al.
Publicado: (2019)

Comunicación política y campañas electorales : estrategias en elecciones presidenciales /
por: García Beaudoux, Virginia
Publicado: (2005)

Use of a KIT-specific monoclonal antibody to bypass imatinib resistance in gastrointestinal stromal tumors
por: Edris, Badreddin, et al.
Publicado: (2013)

Imatinib mesylate treatment in a dog with gastrointestinal stromal tumors with a c-kit mutation
por: IRIE, Mitsuhiro, et al.
Publicado: (2015)

Impact of the KIT/PDGFRA genotype on prognosis in imatinib‐naïve Japanese patients with gastrointestinal stromal tumor
por: Cho, Haruhiko, et al.
Publicado: (2021)

Primary penile melanoma and genital lichen sclerosus
por: Dear, Kate, et al.
Publicado: (2023)

Aging Kit Mutant Mice Develop Cardiomyopathy
por: Ye, Lei, et al.
Publicado: (2012)

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas
por: Satzger, I, et al.
Publicado: (2008)

Imatinib Responsiveness in Canine Mast Cell Tumors Carrying Novel Mutations of c-KIT Exon 11
por: NAKANO, Yuko, et al.
Publicado: (2013)

Two different KIT mutations may lead to different responses to imatinib in metastatic gastrointestinal stromal tumor
por: Yim, Eunjung, et al.
Publicado: (2018)

Identification of Thiazolo[5,4-b]pyridine Derivatives as c-KIT Inhibitors for Overcoming Imatinib Resistance
por: Nam, Yunju, et al.
Publicado: (2022)

Phase II trial of imatinib mesylate in patients with metastatic melanoma
por: Kim, K B, et al.
Publicado: (2008)

Synergistic Targeting of DNA-PK and KIT Signaling Pathways in KIT Mutant Acute Myeloid Leukemia
por: Murray, Heather C., et al.
Publicado: (2023)

A Case of Treated Penile Melanoma with Gastric Recurrence
por: Melki, Gabriel, et al.
Publicado: (2021)

Penile melanoma: a pathological report of two cases
por: Pósfai, Boglárka, et al.
Publicado: (2023)

KIT and Melanoma: Biological Insights and Clinical Implications
por: Pham, Duc (Daniel) M., et al.
Publicado: (2020)

Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation
por: Wakai, T, et al.
Publicado: (2004)

Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report
por: Engin, Gulgun, et al.
Publicado: (2017)

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours
por: Serrano, César, et al.
Publicado: (2019)

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate
por: Rausch, Jessica L., et al.
Publicado: (2016)

KIT and PDGFRA Mutations and Survival of Gastrointestinal Stromal Tumor Patients Treated with Adjuvant Imatinib in a Randomized Trial
por: Joensuu, Heikki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_h1fcfh9o4n38am5rcel4gsjf5s